Labradimil

Star0

DB06549InvestigationalSmall molecule

Investigated for use/treatment in brain cancer and pediatric indications.

Mechanism: Pharmacologically active on B2 bradykinin receptor
Curator reviewed
Primary indication: Investigated for use/treatment in brain cancer and pediatric indications.Curator reviewed
Formula / weight: C₄₉H₇₅N₁₅O₁₂S · 1098.29 g/mol (avg)
Code names: RMP-7

Resolves to

Compound

UNII2MK663C346CAS159768-75-9ChEMBLCHEMBL2105864

Structure

InChIKeyIDXCXSCCZNCXCL-XMADEQCMSA-NSMILES

COC1=CC=C(C[C@@H](CN[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CS2)NC(=O)CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CCCN=C(N)N)C=C1

Targets

P30411BDKRB2

What you can answer from here — as of May 06, 2022

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Labradimil, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account